1. Home
  2. APLT vs ETW Comparison

APLT vs ETW Comparison

Compare APLT & ETW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APLT
  • ETW
  • Stock Information
  • Founded
  • APLT 2016
  • ETW 2005
  • Country
  • APLT United States
  • ETW United States
  • Employees
  • APLT N/A
  • ETW N/A
  • Industry
  • APLT Biotechnology: Pharmaceutical Preparations
  • ETW Investment Managers
  • Sector
  • APLT Health Care
  • ETW Finance
  • Exchange
  • APLT Nasdaq
  • ETW Nasdaq
  • Market Cap
  • APLT 128.0M
  • ETW 941.4M
  • IPO Year
  • APLT 2019
  • ETW N/A
  • Fundamental
  • Price
  • APLT $0.90
  • ETW $8.41
  • Analyst Decision
  • APLT Buy
  • ETW
  • Analyst Count
  • APLT 7
  • ETW 0
  • Target Price
  • APLT $6.10
  • ETW N/A
  • AVG Volume (30 Days)
  • APLT 8.4M
  • ETW 284.6K
  • Earning Date
  • APLT 11-07-2024
  • ETW 01-01-0001
  • Dividend Yield
  • APLT N/A
  • ETW 8.61%
  • EPS Growth
  • APLT N/A
  • ETW N/A
  • EPS
  • APLT N/A
  • ETW N/A
  • Revenue
  • APLT N/A
  • ETW N/A
  • Revenue This Year
  • APLT N/A
  • ETW N/A
  • Revenue Next Year
  • APLT $2,664.24
  • ETW N/A
  • P/E Ratio
  • APLT N/A
  • ETW N/A
  • Revenue Growth
  • APLT N/A
  • ETW N/A
  • 52 Week Low
  • APLT $0.77
  • ETW $6.96
  • 52 Week High
  • APLT $10.62
  • ETW $8.49
  • Technical
  • Relative Strength Index (RSI)
  • APLT 19.46
  • ETW 42.03
  • Support Level
  • APLT $0.78
  • ETW $8.35
  • Resistance Level
  • APLT $0.90
  • ETW $8.46
  • Average True Range (ATR)
  • APLT 0.12
  • ETW 0.11
  • MACD
  • APLT 0.26
  • ETW -0.01
  • Stochastic Oscillator
  • APLT 20.97
  • ETW 30.77

About APLT Applied Therapeutics Inc.

Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.

About ETW Eaton Vance Corporation Eaton Vance Tax-Managed Global Buy-Write Opportunites Fund of Beneficial Interest

Eaton Vance Tax-mangd Glo Buy-write Oppo is a United States-based diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary objective of the fund is capital appreciation. The fund invests in a diversified portfolio of common stocks and writes call options on one or more U.S. indices on a substantial portion of the value of its common stock portfolio to generate current earnings from the option premium. Its portfolio of investments consists of the capital markets, chemicals, banks, biotechnology, media, and other sectors.

Share on Social Networks: